期刊
VACCINE
卷 19, 期 15-16, 页码 2080-2091出版社
ELSEVIER SCI LTD
DOI: 10.1016/S0264-410X(00)00415-1
关键词
QS-21; gp120 HIV-1MN protein; immunization
资金
- NIAID NIH HHS [N01 AI-45211, N01 AI-45210, N01 AI-45209, N01 AI-65305, N01 AI-45212, AI-82500, N01 AI-45208] Funding Source: Medline
Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1(MN) protein (rsgp120) immunization. The QS-21 was administered at two doses (50 and 100 mug), either alone or in combination with aluminum hydroxide (600 mug). At the highest doses of rsgp120 (100, 300, and 600 mug). QS-21 exerted no significant effect on either binding or neutralizing antibody titers. Antibody binding and neutralizing responses fell dramatically when rsgp120, formulated with alum alone, was given at low doses (3 and 30 mug). In contrast, antibody responses similar in titer to those in the high dose antigen groups were induced with the low dose rsgp120 formulated with QS-21. In addition, the lymphocyte proliferation and delayed type hypersensitivity skin testing were superior in the QS-21 recipients compared with the alum recipients at the low antigen doses. Moderate to severe pain was observed in majority of the volunteers receiving QS-21 formulations, and vasovagal episodes and hypertension were not infrequent. Thus, the use of QS-21 may provide a means to reduce the dose of a soluble protein immunogen. (C) 2001 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据